Tower Research Capital LLC (Trc) Uro Gen Pharma Ltd. Transaction History
Tower Research Capital LLC (Trc)
- $4.87 Billion
- Q4 2024
A detailed history of Tower Research Capital LLC (Trc) transactions in Uro Gen Pharma Ltd. stock. As of the latest transaction made, Tower Research Capital LLC (Trc) holds 1,585 shares of URGN stock, worth $16,975. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,585
Previous 1,778
10.85%
Holding current value
$16,975
Previous $22,000
27.27%
% of portfolio
0.0%
Previous 0.0%
Shares
30 transactions
Others Institutions Holding URGN
# of Institutions
137Shares Held
36.2MCall Options Held
57.7KPut Options Held
9.8K-
Rtw Investments, LP New York, NY3.83MShares$41.1 Million0.67% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA2.93MShares$31.4 Million0.06% of portfolio
-
Menora Mivtachim Holdings Ltd.2.3MShares$24.7 Million0.15% of portfolio
-
Black Rock Inc. New York, NY2.19MShares$23.5 Million0.0% of portfolio
-
Toronto Dominion Bank Toronto, Ontario, A61.75MShares$18.7 Million0.03% of portfolio
About UroGen Pharma Ltd.
- Ticker URGN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 22,740,500
- Market Cap $244M
- Description
- UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead...